Stratosvir
Stevenage, GB · 2 known investors
Find your way into Stratosvir
372 people in our graph share verified history with the Stratosvir team — schools, employers, funds. One of them is your warm intro.
Drew Burdonunlockedknows Antonio Postigo · together at Cancerresearchuk (overlapped)
×2knows the team · via Imperial College London
×2knows the team · via Cancerresearchuk
×2knows the team · via The Francis Crick Institute
knows the team · via Deep Science Ventures
×4knows the team · via University of Groningen
Stratosvir develops engineered viral immunotherapy treatments for advanced cancers, including prostate cancer, using modified viruses to activate the body's immune system against tumors. The company targets patients with advanced solid tumors where current treatment options are limited.
Founders & leadership
DC
Dr Chris UllmaninCEO
AP
Antonio PostigoinCSOAntonio Postigo is Chief Scientific Officer of Stratosvir, which develops engineered viral immunotherapy treatments for advanced cancers. He brings experience as an R&D scientist and bioentrepreneur in advanced therapeutic development.
Board
PM
Priya MandeinChairman
Investors · 2
Companies House · registry record
View on Companies House ↗- Registered name
- STRATOSVIR LIMITED
- Company number
- 13099988
- Status
- Active
- Company type
- Private limited company
- Incorporated
- 24 Dec 2020
- Registered office
- 46-54 High Street, Ingatestone, CM4 9DW
- Nature of business (SIC)
- 72110 — Research and experimental development on biotechnology
- Accounts
- last made up to 31 Mar 2025 · next due 31 Dec 2026
- Confirmation statement
- last made up to 24 Dec 2025 · next due 7 Jan 2027
Current officers · 4
- Laura Margaret Fletcher — director, appointed 10 May 2021
- Priya Mande — director, appointed 6 Nov 2023
- Juan Antonio Postigo — director, appointed 10 May 2021
- Christopher Graeme Ullman — director, appointed 24 Dec 2020
Source: Companies House public register · retrieved 6 Aug 2026. Contains public sector information licensed under the Open Government Licence v3.0.
In the news
Frequently asked questions
- What does Stratosvir do?
- Stratosvir develops engineered viral immunotherapy treatments for advanced cancers, including prostate cancer, using modified viruses to activate the body's immune system against tumors. The company targets patients with advanced solid tumors where current treatment options are limited.
- Who are Stratosvir's investors?
- Stratosvir's investors include Deep Science Ventures, O2h Ventures.
- Where is Stratosvir headquartered?
- Stratosvir is headquartered in Stevenage, GB.